JP7039582B2 - 活性化可能な抗ｃｔｌａ－４抗体およびその使用 - Google Patents

活性化可能な抗ｃｔｌａ－４抗体およびその使用 Download PDF

Info

Publication number
JP7039582B2
JP7039582B2 JP2019523779A JP2019523779A JP7039582B2 JP 7039582 B2 JP7039582 B2 JP 7039582B2 JP 2019523779 A JP2019523779 A JP 2019523779A JP 2019523779 A JP2019523779 A JP 2019523779A JP 7039582 B2 JP7039582 B2 JP 7039582B2
Authority
JP
Japan
Prior art keywords
antibody
seq
ctla
cancer
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500016A5 (enExample
JP2020500016A (ja
Inventor
キンバリー・アン・ティプトン
ジェイムズ・ウィリアム・ウエスト
シュリカント・デシュパンデ
ジョン・ジェイ・エンゲルハート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020500016A publication Critical patent/JP2020500016A/ja
Publication of JP2020500016A5 publication Critical patent/JP2020500016A5/ja
Priority to JP2022036450A priority Critical patent/JP7472183B2/ja
Application granted granted Critical
Publication of JP7039582B2 publication Critical patent/JP7039582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
JP2019523779A 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用 Active JP7039582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022036450A JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417212P 2016-11-03 2016-11-03
US62/417,212 2016-11-03
PCT/US2017/059740 WO2018085555A1 (en) 2016-11-03 2017-11-02 Activatable anti-ctla-4 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022036450A Division JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020500016A JP2020500016A (ja) 2020-01-09
JP2020500016A5 JP2020500016A5 (enExample) 2020-12-10
JP7039582B2 true JP7039582B2 (ja) 2022-03-22

Family

ID=61132883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523779A Active JP7039582B2 (ja) 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Country Status (20)

Country Link
US (2) US11117968B2 (enExample)
EP (1) EP3535300B1 (enExample)
JP (2) JP7039582B2 (enExample)
KR (2) KR102584340B1 (enExample)
CN (1) CN110072890B (enExample)
AR (1) AR110678A1 (enExample)
AU (1) AU2017355446A1 (enExample)
BR (1) BR112019008223A2 (enExample)
CA (1) CA3042679A1 (enExample)
CL (1) CL2019001226A1 (enExample)
CO (1) CO2019004469A2 (enExample)
EA (1) EA201990875A1 (enExample)
ES (1) ES3053667T3 (enExample)
IL (1) IL265625A (enExample)
MX (1) MX2019004775A (enExample)
MY (1) MY200695A (enExample)
PE (1) PE20191131A1 (enExample)
SG (1) SG11201902857SA (enExample)
TW (2) TW202334213A (enExample)
WO (1) WO2018085555A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX379106B (es) 2013-09-25 2025-03-11 Cytomx Therapeutics Inc Substratos de metaloproteinasas de matriz y otras porciones escindibles y métodos para usar los mismos.
IL317045A (en) 2014-01-31 2025-01-01 Cytomx Therapeutics Inc Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
JP7001615B2 (ja) 2016-11-28 2022-02-03 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
KR102522693B1 (ko) 2017-05-19 2023-04-17 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
EP3706803A4 (en) 2017-11-08 2021-08-04 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. CONJUGATES BASED ON A BIOMOLECULE AND THEIR USE
SG11202004627WA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand-binding activity
JP7482630B2 (ja) * 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
KR20210141447A (ko) 2018-12-26 2021-11-23 실리오 디벨럽먼트, 인크. 항-ctla4 항체 및 이의 사용 방법
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CN110498856B (zh) * 2019-09-17 2020-08-11 浙江玉安康瑞生物科技有限公司 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途
MX2022005474A (es) 2019-11-08 2022-06-02 Bristol Myers Squibb Co Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
AU2021208642B2 (en) * 2020-01-17 2025-06-05 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
PH12022552632A1 (en) * 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-12 cytokines and their cleavage products
IL296634A (en) 2020-04-09 2022-11-01 Cytomx Therapeutics Inc Preparations containing activatable antibodies
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
CA3187754A1 (en) 2020-08-11 2022-02-17 David Campbell Cleavable linker compositions and methods
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
CA3209364A1 (en) * 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
JP2024523443A (ja) 2021-06-21 2024-06-28 ブリストル－マイヤーズ スクイブ カンパニー 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス，インク． 活性化可能な二重アンカー型マスク化分子及びその使用方法
WO2023192606A2 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
US20250215110A1 (en) 2022-04-01 2025-07-03 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
EP4565250A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性部分及びその使用方法
EP4565261A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
JP2025525879A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性基質及びその使用方法
TW202424184A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers
CN120019078A (zh) * 2022-09-02 2025-05-16 西奇利德股份有限公司 抗ctla-4单克隆抗体及其用途
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2024216146A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU9399501A (en) 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR101291640B1 (ko) 2005-02-18 2013-08-05 메다렉스, 엘.엘.시. 푸코실 잔기가 결핍된 전립선 특이적 막 항원(ｐｓｍａ)에대한 단클론성 항체
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
WO2007084672A2 (en) 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
AU2007308983B2 (en) 2006-10-24 2012-12-06 Emergent Product Development Seattle, Llc A method for increasing antibody-dependent cytotoxicity with castanospermine
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
WO2012112687A1 (en) * 2011-02-15 2012-08-23 Immunogen, Inc. Methods of preparation of conjugates
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2854843A4 (en) 2012-05-31 2016-06-01 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1
US9127053B2 (en) 2012-06-22 2015-09-08 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
PL2925350T3 (pl) * 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
CA2913977C (en) 2013-05-31 2022-11-29 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CA3078121A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3059319A4 (en) 2013-10-07 2017-04-26 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
EP3237446B1 (en) 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
EP3733696A1 (en) * 2015-01-13 2020-11-04 City of Hope Ctla4-binding protein peptide-linker masks
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
SI3334763T1 (sl) 2015-08-11 2025-01-31 WuXi Biologics Ireland Limited Nova protitelesa proti pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
WO2017123557A1 (en) 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
KR20200040819A (ko) 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
MY200695A (en) 2024-01-11
SG11201902857SA (en) 2019-05-30
KR102814027B1 (ko) 2025-05-27
TWI784983B (zh) 2022-12-01
TW201819412A (zh) 2018-06-01
ES3053667T3 (en) 2026-01-23
US20190359714A1 (en) 2019-11-28
JP7472183B2 (ja) 2024-04-22
US11117968B2 (en) 2021-09-14
JP2022091800A (ja) 2022-06-21
AR110678A1 (es) 2019-04-24
KR20230141941A (ko) 2023-10-10
EP3535300B1 (en) 2025-10-22
MX2019004775A (es) 2019-08-05
EA201990875A1 (ru) 2019-09-30
TW202334213A (zh) 2023-09-01
KR102584340B1 (ko) 2023-10-10
CL2019001226A1 (es) 2019-09-13
EP3535300A1 (en) 2019-09-11
IL265625A (en) 2019-05-30
PE20191131A1 (es) 2019-09-02
WO2018085555A1 (en) 2018-05-11
US12441799B2 (en) 2025-10-14
CN110072890B (zh) 2022-11-29
US20220089734A1 (en) 2022-03-24
BR112019008223A2 (pt) 2019-07-16
JP2020500016A (ja) 2020-01-09
WO2018085555A8 (en) 2018-05-31
CA3042679A1 (en) 2018-05-11
CO2019004469A2 (es) 2019-05-10
AU2017355446A1 (en) 2019-05-02
KR20190072626A (ko) 2019-06-25
CN110072890A (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
JP7472183B2 (ja) 活性化可能な抗ｃｔｌａ－４抗体およびその使用
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
JP7351845B2 (ja) Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
US20220048996A1 (en) Antibody molecules that bind cd137 and ox40
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
CN114874331A (zh) 治疗性抗体和它们的用途
JP2022529939A (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2015188047A1 (en) ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
JP2024539650A (ja) 活性化可能なポリペプチド複合体
KR20240111823A (ko) 항-cd47 항체 및 이의 사용 방법
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
CA3209364A1 (en) Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
US20250243283A1 (en) Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
EA043382B1 (ru) Активируемые антитела против ctla-4 и их применение
US20250179204A1 (en) Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
HK1258304A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
HK1258304B (en) Optimized anti-cd3 bispecific antibodies and uses thereof
EA040594B1 (ru) Оптимизированные биспецифические анти-cd3 антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250